“A real-world evidence” in reduction of volatile anesthetics by BIS-guided anesthesia

Yan-Yuen Poon1,3, Han-Chen Chang1,3, Min-Hsien Chiang1, Kuo-Chuan Hung2, Hsiao-Feng Lu1, Chih-Hsien Wang1, Jo-Chi Chin1 & Shao-Chun Wu1,3*

Many well-controlled clinical studies have shown that BIS-guided anesthesia could prevent intraoperative awareness and improve postoperative morbidity and mortality, by optimizing the amount of volatile anesthetics administered to patients. However, we questioned if the previously reported advantages of BIS-guided anesthesia in controlled studies would still apply in real-world settings. This retrospective study based on real-world settings clarified the role of BIS-guided anesthesia in reducing anesthetic consumption. We obtained anesthesia records from an electronic database of a medical center in southern Taiwan. A total of 6,713 cases were enrolled, where 1,324 cases receiving sevoflurane underwent BIS-guided anesthesia and 378 received desflurane; further, 3,819 receiving sevoflurane underwent standard anesthesia practice and 1,192 cases received desflurane. The median (25–75% interquartile values) of the average hourly consumption of sevoflurane or desflurane decreased significantly under BIS-guided anesthesia [10.5 (8.7–13.0) mL/h and 17.4 (13.7–21.1) mL/h, respectively] compared to that under standard anesthesia practice [11.4 (9.0–14.5) mL/h, and 20.2 (15.8–25.0), mL/h, respectively]. Furthermore, the average hourly consumption of these two volatile anesthetics varied inversely with age and anesthesia time in both groups. A significant reduction was found in the hourly consumption of volatile anesthetics in patients under BIS-guided anesthesia compared to standard anesthesia practice in different age groups or different anesthesia time. We concluded that BIS-guided anesthesia could reduce consumption of volatile anesthetics in real-world settings as well.

Bispectral index monitor (BIS) is an anesthesia depth measurement tool that has gained clinical popularity in recent years after many clinical trials supported its use in lowering the risk of intraoperative awareness, shortening recovery time, and improving postoperative morbidity and mortality. In these studies, BIS reduced the total use of anesthetic agents, reducing the total anesthesia cost compared with standard anesthesia practice1. Consumption of volatile anesthetics in BIS-guided anesthesia ensures the appropriate amount given and, more importantly, prevents intraoperative awareness. Conventional, well-controlled clinical trials utilized different tools to estimate volatile anesthetic consumption, and most results point to reduced anesthetic consumption in BIS-guided anesthesia2–6. These traditional clinical trials were conducted with a specific study population, in specialized environments, and adhere to a list of eligibility criteria to control variability and ensure the quality of the data7. However, in practice, restrictions or patient selections would not be ethically acceptable. The impetus for this study comes from the notion that conventional studies do not always reflect the real-world settings. With modern, sophisticated anesthesia machines available that calculate volatile anesthetics consumed during each anesthesia and the accessibility to electronic anesthesia records, we can identify the inter-relationships of volatile anesthetics consumed in each anesthesia versus various independent variables under real-world settings. Distinct from previous well-controlled clinical trials that investigated the influence of BIS-guided general anesthesia on intraoperative minimal alveolar concentration (MAC)7, we investigated the role of BIS-guided general anesthesia on the reduction of volatile anesthetics based on a real-world setting.

1Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, No. 123, Ta-Pei Rd., Niao-Song Dist., Kaohsiung City 833, Taiwan. 2Department of Anesthesiology, Chi Mei Medical Center, No.901, Zhonghua Rd. Yongkang Dist., Tainan City 710, Taiwan. 3These authors contributed equally: Yan-Yuen Poon and Han-Chen Chang. *email: shaochunwu@gmail.com
Results

A total of 13,027 general anesthesia records from May 1st, 2017 to Aug 31st, 2017, were retrieved from our hospital's electronic database. We recruited 6,803 cases after excluding those with ambulatory surgeries, sedated endoscopy, pediatric surgery, and those with missing data. Table 1 summarizes the demographic characteristics of the cases. Cases were stratified into five different categories: anesthesia time, age, gender, ASA physical status, and surgical entities. For statistical purposes, infrequently performed surgeries during the study period were excluded from this study. These included dental surgery (n = 49), CAPD catheter implantation (n = 32), and radiological procedures (n = 9) (Table 1). Finally, a total of 6,713 cases of volatile general anesthesia were included for statistical analysis (Fig. 1).

The general relationship between the hourly consumption of volatile anesthetics and anesthesia times were shown in Fig. 2a,b, respectively. A series of parallel counter curves illustrate a decrease in hourly consumption of volatile anesthetics versus anesthesia time in both sevoflurane (Fig. 2a) and desflurane (Fig. 2b) irrespective of anesthesia practice. The median (25–75% interquartile values) of the hourly consumption of sevoflurane and desflurane in all surgeries (Table 2) under BIS-guide anesthesia were 10.5 (8.7–13.0) mL/h and 17.4 (13.7–21.1) mL/h respectively which were significantly lesser than the corresponding hourly consumptions under standard anesthesia practice [11.4 (9.0–14.5) mL/h, and 20.2 (15.8–25.0) mL/h, respectively].

We also evaluated the effect of anesthesia time on the consumption of volatile anesthetics. Patients with different anesthesia time were divided into five groups for comparisons. The hourly consumption of sevoflurane

| Anesthesia time | Total case numbers n (%) | BIS n (%) | Standard practice n (%) |
|-----------------|--------------------------|-----------|-------------------------|
| <2 h            | 1,620 (23.8%)            | 276 (16.1%)| 1,344 (26.4%)           |
| 2–4 h           | 3,205 (47.1%)            | 746 (43.6%)| 2,459 (48.3%)           |
| 4–6 h           | 1,209 (17.8%)            | 372 (21.7%)| 837 (16.4%)             |
| 6–8 h           | 424 (6.2%)               | 175 (10.2%)| 249 (4.9%)              |
| ≥8–10 h         | 345 (5.1%)               | 143 (8.4%) | 202 (4.0%)              |

| Age (years old) | Total case numbers n (%) | BIS n (%) | Standard practice n (%) |
|-----------------|--------------------------|-----------|-------------------------|
| 21–40           | 1,279 (18.8%)            | 224 (13.1%)| 1,055 (20.7%)           |
| 41–60           | 2,615 (38.4%)            | 634 (37.0%)| 1,981 (38.9%)           |
| 61–80           | 2,622 (38.5%)            | 768 (44.9%)| 1,854 (36.4%)           |
| > 80            | 287 (4.2%)               | 86 (5.0%)  | 201 (3.9%)              |

| Gender (M/F)    | Total case numbers n (%) | BIS n (%) | Standard practice n (%) |
|-----------------|--------------------------|-----------|-------------------------|
| Male            | 3,413 (50.2%)            | 743 (43.4%)| 2,421 (47.6%)           |
| Female          | 3,390 (49.8%)            | 969 (56.6%)| 2,670 (52.4%)           |

| Weight (kg)     | Total case numbers n (%) | BIS n (%) | Standard practice n (%) |
|-----------------|--------------------------|-----------|-------------------------|
| 65.25±13.25     | 64.94±13.79              | 66.47±22.19|

| ASA physical status | Total case numbers n (%) | BIS n (%) | Standard practice n (%) |
|---------------------|--------------------------|-----------|-------------------------|
| 1                   | 370 (5.4%)               | 86 (5.0%)  | 284 (5.6%)              |
| 2                   | 3,880 (57.1%)            | 978 (57.2%)| 2,902 (57.0%)           |
| 3                   | 2,419 (35.6%)            | 636 (37.2%)| 1,783 (35.0%)           |
| 4                   | 124 (1.8%)               | 10 (0.6%)  | 114 (2.2%)              |
| 5                   | 7 (0.1%)                 | 0 (0.0%)   | 7 (0.1%)                |

| Surgery            | Total case numbers n (%) | BIS n (%) | Standard practice n (%) |
|--------------------|--------------------------|-----------|-------------------------|
| Cardiothoracic vascular | 299 (4.4%)               | 134 (7.8%)| 165 (3.2%)              |
| Otolaryngology     | 510 (7.5%)               | 78 (4.6%) | 432 (8.5%)              |
| General            | 1,167 (17.2%)            | 511 (29.8%)| 656 (12.9%)             |
| Urology            | 632 (9.3%)               | 157 (9.2%)| 475 (9.3%)              |
| Gynecology         | 521 (7.7%)               | 178 (10.4%)| 343 (6.7%)              |
| Neurosurgery       | 564 (8.3%)               | 114 (6.7%)| 450 (8.8%)              |
| Ophthalmology      | 219 (3.2%)               | 29 (1.7%)  | 190 (3.7%)              |
| Orthopedics        | 1517 (22.3%)             | 246 (14.4%)| 1,271 (25.0%)           |
| Plastic reconstructive | 556 (8.2%)               | 22 (1.3%) | 534 (10.5%)             |
| Colo-rectal        | 354 (5.2%)               | 166 (9.7%)| 188 (3.7%)              |
| Trauma             | 374 (5.5%)               | 67 (3.9%)  | 307 (6.0%)              |
| Dental surgery     | 49 (0.7%)                | 0 (0.0%)   | 49 (1.0%)               |
| CAPD catheter implantation | 32 (0.5%)             | 9 (0.5%)  | 23 (0.5%)               |
| Radiology          | 9 (0.1%)                 | 1 (0.1%)   | 8 (0.2%)                |

Table 1. Demographic characteristics of (N = 6,803) in adult hospitalized surgery from May 1st, 2017 to Aug 31st, 2017.
Figure 1. Flow diagram of Adult Volatile Anesthesia analyzed in this study.

Figure 2. Indicate hourly consumption of sevoflurane (a) or desflurane (b) versus anesthesia time in BIS guided and Standard practice group.

| Group | BIS (mL/h) | Standard practice (mL/h) | P  |
|-------|------------|--------------------------|----|
| Sevoflurane (median [25–75% interquartile values]) | 10.5 (8.7–13.0), n = 1,324 | 11.4 (9.0–14.5), n = 3,819 | <0.001 |
| Desflurane (median [25–75% interquartile values]) | 17.4 (13.7–21.1), n = 378 | 20.2 (15.8–25.0), n = 1,192 | <0.001 |
| Sevoflurane (mean [95% CI]) | 2 h | 11.5 (11.2–11.7), n = 1,324 | 12.3 (12.2–12.5), n = 3,819 | <0.001 |
| | 4 h | 11.2 (10.9–11.4), n = 1,102 | 12.0 (11.94–12.2), n = 2,759 | <0.001 |
| | 6 h | 10.6 (10.2–10.9), n = 529 | 11.7 (11.4–12.0), n = 992 | <0.001 |
| | 8 h | 10.1 (9.6–10.6), n = 255 | 11.0 (10.5–11.5), n = 347 | 0.016 |
| | ≥ 10 h | 9.4 (8.9–9.9), n = 123 | 10.0 (9.3–10.8), n = 155 | 0.160 |
| Desflurane (mean [95% CI]) | 2 h | 18.3 (17.6–19.0), n = 378 | 20.9 (20.5–21.4), n = 1,192 | <0.001 |
| | 4 h | 18.2 (17.4–19.0), n = 332 | 20.8 (20.3–21.3), n = 944 | <0.001 |
| | 6 h | 17.2 (16.2–18.2), n = 161 | 19.0 (18.1–19.8), n = 279 | 0.009 |
| | 8 h | 17.5 (15.9–19.1), n = 63 | 18.0 (16.5–19.6), n = 91 | 0.643 |
| | ≥ 10 h | 16.4 (13.5–19.2), n = 20 | 17.9 (15.3–20.5), n = 36 | 0.433 |

Table 2. Consumption of volatile anesthetic guided by BIS or standard practice by anesthesia time. Data were expressed as median (25–75% interquartile values) or mean (95% CI).
was significantly less in 2 h, 4 h, 6 h, and 8 h anesthesia times under BIS-guided anesthesia as compared with the corresponding anesthesia times under standard anesthesia practice (Table 2, Fig. 3a). Similarly, the hourly consumption of desflurane was significantly lesser in 2 h, 4 h, 6 h anesthesia time under BIS-guided anesthesia than the corresponding anesthesia times under standard anesthesia practice (Table 2, Fig. 3b).

We then evaluated the effect BIS-guided anesthesia had on reducing volatile anesthetics among different age groups. The hourly consumption of sevoflurane was significantly lower in BIS-guided anesthesia than in standard anesthesia practice in the 21–40, 41–60, and 61–80 year-old groups, as shown in Table 3 and Fig. 4a. The hourly consumption of desflurane was significantly lower in BIS-guided anesthesia than in standard anesthesia practice for the 21–40 and 41–60 year-old groups (Table 3 and Fig. 4b).

Gender effects on the hourly consumption of volatile anesthetics in BIS-guided anesthesia and standard anesthesia practice were evaluated. In BIS-guided anesthesia and standard anesthesia practice, the hourly consumption of desflurane was significantly lower in female patients than in male patients. The hourly consumption of desflurane was significantly lower in female patients in standard anesthesia practice (Table 4).

Postoperative events in BIS and Standard practice groups was shown in Table 5. The occurrence of intraoperative awareness was 0.1% in BIS group and 0.1% in standard anesthesia group without significant difference. The occurrence of postoperative headache or dizziness was 1.8% in BIS group and 1.4% in standard anesthesia group without significant difference. The occurrence of postoperative nausea and vomiting was 12.4% in BIS group and 14.1% in standard anesthesia group without significant difference. The occurrence of postoperative respiratory event was 2.4% in BIS group and 1.7% in standard anesthesia group without significant difference. The occurrence of cerebrovascular event was 0.2% in BIS group and 0.2% in standard anesthesia group without significant difference. Patients' satisfaction showed no significant difference between two groups.

**Discussion**

Since the introduction of BIS monitor to anesthesia in 1994, numerous clinical trials have been carried out to evaluate its efficacy in preventing intraoperative awareness, lowering postoperative morbidity and mortality, enhancing early postoperative recovery, and reducing intraoperative consumption of volatile anesthetics. It is reasonable to speculate that more than adequate consumption of volatile anesthetics may

---

**Table 3.** Consumption of volatile anesthetic guided by BIS or Blood pressure by age. Data were expressed as median (25%-75% interquartile values).

| Age (years old) | BIS (mL/h) | Standard practice (mL/h) | P   |
|-----------------|------------|--------------------------|-----|
| Sevoflurane     |            |                          |     |
| 21–40           | 10.8 (8.8–13.6) (n = 152) | 12.7 (10.2–16.0) (n = 741) | < 0.001 |
| 41–60           | 10.9 (8.9–13.5) (n = 483) | 11.8 (9.4–14.9) (n = 1,491) | < 0.001 |
| 61–80           | 10.3 (8.4–12.6) (n = 616) | 10.6 (8.5–13.5) (n = 1,429) | 0.032 |
| > 80            | 9.6 (7.7–11.9) (n = 73) | 8.9 (7.4–11.2) (n = 158) | 0.461 |
| Desflurane      |            |                          |     |
| 21–40           | 18.2 (14.3–22.2) (n = 70) | 22.0 (17.4–27.7) (n = 299) | < 0.001 |
| 41–60           | 17.1 (13.5–21.1) (n = 147) | 21.1 (16.6–25.5) (n = 447) | < 0.001 |
| 61–80           | 17.6 (14.0–21.0) (n = 148) | 18.6 (15.0–23.1) (n = 403) | 0.095 |
| > 80            | 11.8 (10.2–16.0) (n = 13) | 16.2 (12.2–19.6) (n = 43) | 0.053 |
Figure 4. Hourly consumption of BIS-guided and Standard practice group in sevoflurane (a) or desflurane (b) volatile anesthetics in 4 groups of age.

Table 4. Consumption of volatile anesthetic guided by BIS or Standard practice by gender. Data were expressed as median (25–75% interquartile values).

|                  | Male                        | Female                      | P   |
|------------------|-----------------------------|-----------------------------|-----|
| **Sevoflurane**  |                             |                             |     |
| BIS (mL/h)       | 10.8 (9.0–13.6) (n = 596)   | 10.1 (8.5–12.5) (n = 728)   | 0.001|
| Standard practice (mL/h) | 11.9(9.4–15.2) (n = 2019) | 10.8(8.7–13.6) (n = 1,800) | < 0.001|
| **Desflurane**   |                             |                             |     |
| BIS (mL/h)       | 17.7 (13.9–21.8)(n = 142)   | 17.2 (13.4–20.9) (n = 236)  | 0.437|
| Standard practice (mL/h) | 22.1 (17.0–27.7) (n = 599) | 19.0 (15.1–22.8) (n = 593) | < 0.001|

Table 5. Postoperative events in BIS and Standard practice groups. *Data were expressed as median (25–75% interquartile values).

|                              | BIS n (%) | Standard practice n (%) | P   |
|------------------------------|-----------|-------------------------|-----|
| **Intraoperative awareness** |           |                         | 0.663|
| No                           | 1,700 (99.9%) | 5,007 (99.9%)             |     |
| Yes                          | 2 (0.1%)   | 4 (0.1%)                 |     |
| **Headache/dizziness**       |           |                         | 0.191|
| No                           | 1,671 (98.2%) | 4,942 (98.6%)            |     |
| Yes                          | 31 (1.8%)  | 69 (1.4%)                |     |
| **Postoperative nausea/vomiting** |       |                         | 0.076|
| No                           | 1,491 (87.6%) | 4,304 (85.9%)            |     |
| Yes                          | 211 (12.4%) | 707 (14.1%)              |     |
| **Respiratory event**        |           |                         | 0.061|
| No                           | 1,661 (97.6%) | 4,926 (98.3%)            |     |
| Yes                          | 41 (2.4%)  | 85 (1.7%)                |     |
| **Cerebrovascular event**    |           |                         | 0.785|
| No                           | 1,698 (99.8%) | 5,001 (99.8%)            |     |
| Yes                          | 4 (0.2%)   | 10 (0.2%)                |     |
| **Patients’ satisfaction**   | 4.0 (4.0–5.0)* | 4.0 (4.0–5.0)*        | 0.077|

*Data were expressed as median (25–75% interquartile values).
increase the risk of unwanted postoperative side effects. Many well-controlled clinical trials supported the role of BIS-guided anesthesia in maintaining an adequate level of anesthesia without an overdose of volatile anesthetics. However, experiences in the real-world may differ from well-controlled settings; results from well-controlled studies may have interpretation bias in real-world settings. The results support the role of BIS-guided anesthesia on conserving volatile anesthetics consumption based on real-world evidence. The meta-analysis by Gao et al. showed that BIS monitoring has no obviously advantage in decreasing periopeative awareness incidence in volatile anesthesia. The occurrence of intraoperative awareness in our results has the same consequent.

One of the interesting findings revealed in this study was a series of parallel counter curves either in BIS-guided anesthesia or in standard anesthesia practice shown in the scatter diagrams (Fig. 2a,b). These parallel counter curves resembled the pharmacokinetic profiles of volatile anesthetics. High hourly consumptions of both volatile anesthetics were recorded in most surgeries that lasted less than 1 h, which reflected the early phase of uptake of volatile anesthetics when high concentration gradient existed between alveolar and exogenous gas supply. A “genuflection” followed in surgeries of 2-h duration, which marked the transition from the active uptake phase to an equilibrium state. In surgeries lasting more than 2 h, the hourly consumption became fairly constant, and it denoted that an equilibrium state was attained. The physicochemical properties of these two volatile anesthetics are different that their rates of uptake should be reflected in the scatter diagrams (Fig. 2a,b); however, more data, especially on desflurane (n = 1,570 in desflurane vs. n = 5,143 in sevoflurane), are needed before a complete pharmacokinetic profile could be constructed for comparison. The hourly consumption of these two volatile anesthetics decreased as the anesthesia times increased (Fig. 3a,b), and the consumption of these two volatile anesthetics was significantly lesser under BIS-guided anesthesia than under standard anesthesia practice. These results are in accordance with previous clinical studies showing declining consumption of volatile anesthetics as anesthesia time increased. Most pharmacokinetic profiles of volatile anesthetics can only be investigated in sophisticated laboratories or under well-controlled clinical conditions; however, this study may provide an example of utilizing clinical data to establish pharmacokinetic profiles of volatile anesthetics under real-world settings.

Another interesting finding revealed by these parallel counter curves in the scatter diagrams (Fig. 2a,b) was the layout of these counter curves. Further analysis showed that top layer curves represented younger age groups, while lower layer curves represented older age groups. The hourly consumption of the two volatile anesthetics was decreased in elderly patients compared to that in younger patients (Fig. 4a,b). This result is in agreement with the results of previous clinical studies showing less uptake of volatile anesthetics in elderly patients.

Different reports utilize various ways to estimate the consumption of volatile anesthetics. Punjasawadwong et al. in his review article reported BIS-guided anesthesia reduced the requirement for volatile anesthetics (desflurane, sevoflurane, isoflurane) by 0.65 standardized mean difference of minimal alveolar concentration equivalents in 985 patients. Aime et al. reported BIS-guided anesthesia required 29% less sevoflurane in 140 adult patients; the consumption was estimated by weighing sevoflurane vaporizers before and after anesthesia. Basar et al. reported BIS-guided anesthesia reduced sevoflurane usage by 4.37% in 60 adult patients, the consumption of which was estimated by recording the end-tidal sevoflurane concentration every 5 min during surgery, and computed at the conclusion of surgery. Boztug et al. reported BIS-guided anesthesia reduced the maintenance anesthetic concentration by 25% in 50 adult patients. Kreuer et al. reported BIS-guided anesthesia reduced desflurane consumption by 6.6% in 120 adult patients. The consumption was estimated by weighing sevoflurane vaporizers before and after anesthesia. Modern anesthesia machines automatically report the total consumption of volatile anesthetics at the conclusion of each anesthesia, making an accurate estimation of consumption possible in this study. This study provided a more conceivable concept on BIS-guided anesthesia in the reduction of volatile anesthetics consumption than previous studies.

There are some limitations in our study. First, this is a retrospective study, the interpretation of results would be interfered by potential bias. Second, the study focuses on the benefit of volume consumption by BIS-guided general anesthesia. The beneficial of BIS on patients’ safety such as intraoperative vital signs were not investigated. Third, we did not discuss the relation between the decreased volatile anesthetics consumption and the cost reduction. In conclusion, well-controlled clinical studies remain the basis for testing any new drugs or technologies that are to be introduced into real-world practice. Although our study provided real-world evidence to support the role of BIS-guided anesthesia in providing an adequate anesthesia level, more clinical evidence is needed to justify the advances inherent to BIS-guided anesthesia.

Methods
Before beginning, the study was approved by the Institutional Review Board of Kaohsiung Chang Gung Memorial Hospital (IRB number: 201800207B0). Informed consent was waived because of the retrospective nature of the study. All methods were performed in accordance with the relevant guidelines and regulations. We retrieved anesthesia records from May 1st, 2017 to Aug 31st, 2017, from the hospital’s database, and a total of 13,027 general anesthesia records were collected. Exclusion criteria included ambulatory surgeries, sedated endoscopy, pediatric surgeries, a limited number of uncommon procedures (case numbers less than 50), and any record with missing data. Recruited patients received either sevoflurane or desflurane as their primary general anesthetic. The general anesthesia was carried out in semiclosed circuit with fresh gas flow of 1 L/min. The anesthesia machines automatically recorded the consumption of volatile anesthetics at the conclusion of anesthesia. Hourly consumption was calculated depending on the volatile anesthetics consumption and the total anesthesia time. Postoperative daily visit was performed by the well-trained nurse anesthetists and the postoperative events within 72 h including intraoperative awareness, headache or dizziness, postoperative nausea and vomiting, respiratory event, cerebrovascular event, and patients’ satisfaction were recorded.
We divided patients into two major groups as the BIS-guided anesthesia group and the standard anesthesia practice group, and these two groups formed the basis for comparing the consumption of volatile anesthetics in different patients. To elucidate the effect of anesthesia time in these two major groups, we allocated patients according to anesthesia time, namely 2-h, 4-h, 6-h, 8-h, and 10-h. To elucidate the effect of age on the consumption of volatile anesthetics in these two major groups, we stratified patients into four age groups, 21–40 years, 41–60 years, 61–80 years, and over 80 years for comparison.

As a standard practice in our hospital, general anesthesia was induced with propofol (1 to 2 mg/kg). The use of rocuronium (1 mg/kg) or cis-atracurium (0.2 mg/kg), fentanyl (1 mcg/kg) or alfentanil (10 mcg/kg), desflurane (1 to 1.3 MAC) or sevoflurane (1 to 1.3 MAC) depends on the anesthesiologists' preferences. Nitrous oxide, midazolam or other amnestic drugs except propofol was not used in induction and maintenance of general anesthesia in our study. The patient decided whether or not to utilize BIS-guided anesthesia. In the BIS-guided group, the BIS score was kept in the range of 40 to 60 during anesthesia. In the standard anesthesia practice group, volatile anesthetics were titrated against blood pressure and heart rate changes during anesthesia to maintain stable blood pressure and heart rate within 20% of the patient's normal range. A fresh gas flow of 50% oxygen with air was kept to 1 L/min. Maintenance of neuromuscular blocking agents or opioids depended on surgical stimuli, anesthesiologists' preferences, and objective vital signs (more than 20% increase in heart rate, systolic blood pressure and mean arterial pressure). The total consumption of volatile anesthetics was automatically recorded by the anesthesia machine Avance (GE Datex-Ohmeda, Madison, WI), S/5 ADU(GE Datex-Ohmeda, Madison, WI), Carestation 620 (GE Datex-Ohmeda, Madison, WI), or Primus (Drägerwerk, AG, Lübeck, Germany).

**Statistical analysis.** We used the Kolmogorov–Smirnov test to address the normality of continuous variables. Anesthetic consumption (mL/h) were compared by Student's t-test with normal distribution and expressed as mean (95% confidence interval, CI). Non-normally distributed data distribution were expressed as median (25–75% interquartile values) and tested with Mann–Whitney U test. We performed statistical analysis with SPSS version 22.0 (IBM Corp., Armonk, NY, USA) in this study. A P<0.05 was considered statistically significant.

Received: 25 December 2019; Accepted: 28 May 2020
Published online: 09 July 2020

**References**

1. Punjasawadwong, Y., Phongchiewboon, A. & Bunchungmongkol, N. Bispectral index for improving anaesthetic delivery and postoperative recovery. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD003843.pub3 (2014).

2. Boztug, N., Bigat, Z., Akuyuz, M., Demir, S. & Ertok, E. Does using the bispectral index (BIS) during craniotomy affect the quality of recovery. J. Neurosurg. Anesthesiol. 18, 1–4 (2006).

3. Luginbuhl, M., Wuthrich, S., Petersen-Felix, S., Zbinden, A. M. & Schneider, T. W. Different benefit of bispectral index (BIS) in desflurane and propofol anesthesia. Acta Anaesthesiol. Scand. 47, 165–173. https://doi.org/10.1034/j.1399-6573.2003.00041.x (2003).

4. Recart, A. & et al. The effect of cerebral monitoring on recovery after general anesthesia: a comparison of the auditory evoked potential and bispectral index devices with standard clinical practice. Anesth. Analg. 97, 1667–1674. https://doi.org/10.1213/ane.0000000000000403 (2003).

5. Song, D., Jossi, G. P. & White, P. F. Titration of volatile anesthetics using bispectral index facilitates recovery after ambulatory anesthesia. Anesthesiology 87, 842–848. https://doi.org/10.1097/00000542-199710000-00018 (1997).

6. White, P. F. & et al. Does the use of electroencephalographic bispectral index or auditory evoked potential index monitoring facilitate recovery after desflurane anesthesia in the ambulatory setting?. Anesthesiology 100, 811–817. https://doi.org/10.1097/00000542-200404000-00010 (2004).

7. Sherman, R. E. & et al. Real-world evidence—what is it and what can it tell us?. N. Engl. J. Med. 375, 2293–2297. https://doi.org/10.1056/NEJMsB1609216 (2016).

8. Sigl, J. C. & Chamoun, N. G. An introduction to bispectral analysis for the electroencephalogram. J. Clin. Monit. 10, 392–404. https://doi.org/10.1007/bf01618421 (1994).

9. Avidan, M. S. & et al. Prevention of intraoperative awareness in a high-risk surgical population. N. Engl. J. Med. 365, 591–600. https://doi.org/10.1056/NEJMoa110403 (2011).

10. Avidan, M. S. & et al. Anesthesia awareness and the bispectral index. N. Engl. J. Med. 358, 1097–1108. https://doi.org/10.1056/nejmoa0703761 (2008).

11. Maskhour, G. A., Tremper, K. K. & Avidan, M. S. Protocol for the "Michigan Awareness Control Study": A prospective, randomized, controlled trial comparing electronic alerts based on bispectral index monitoring or minimum alveolar concentration for the prevention of intraoperative awareness. BMC Anesthesiol. 9, 7. https://doi.org/10.1186/1471-2253-9-7 (2009).

12. Shu, A. H., Wang, Q. & Chen, X. B. Effect of different depths of anesthesia on postoperative cognitive function in laparoscopic patients: A randomized clinical trial. Curr. Med. Res. Opin. 31, 1883–1887. https://doi.org/10.1185/03007995.2015.1075968 (2015).

13. Nelskyla, K. A., Yli-Hankala, A. M., Puro, P. H. & Korttila, K. T. Sevoflurane titration using bispectral index decreases postoperative vomiting in phase II recovery after ambulatory surgery. Anesth. Analg. 93, 1165–1169. https://doi.org/10.1097/01.aang.00002011.1000-00021 (2001).

14. Kertai, M. D. & et al. Bispectral index monitoring, duration of bispectral index below 45, patient risk factors, and intermediate-term mortality after noncardiac surgery in the B-Unaware Trial. Anesthesiology 114, 545–556. https://doi.org/10.1097/ALN.0b013e31820cb57 (2011).

15. Monk, T. G., Saini, V., Weldon, B. C. & Sigl, J. C. Anesthetic management and one-year mortality after noncardiac surgery. Anesth. Analg. 100, 4–10. https://doi.org/10.1213/ane.00000147519.82841.se (2005).

16. Ciang, M. H., Wu, S. C., Hsu, S. W. & Chin, J. C. Bispectral Index and non-Bispectral Index anesthetic protocols on postoperative recovery outcomes. Minerva Anestesiol. 84, 216–228. https://doi.org/10.23736/s0375-9393.17.12033-x (2018).

17. Ibraheim, O. & et al. Effect of bispectral index (BIS) monitoring on postoperative recovery and sevoflurane consumption among morbidly obese patients undergoing laparoscopic gastric banding. Middle East J. Anaesthesiol. 19, 819–830 (2008).

18. Aime, L. & et al. Does monitoring bispectral index or spectral entropy reduce sevoflurane use?. Anesth. Analg. 103, 1469–1477. https://doi.org/10.1213/ane.0b013e31839153.23 (2006).

19. Basar, H., Ozcan, S., Buyukkokocak, U., Akpinar, S. & Apan, A. Effect of bispectral index monitoring on sevoflurane consumption. Eur. J. Anaesthesiol. 20, 396–400 (2003).
20. Gao, W. W. et al. BIS Monitoring on Intraoperative Awareness: A Meta-analysis. *Curr. Med. Sci.* **38**, 349–353. https://doi.org/10.1007/s11596-018-1886-1 (2018).

21. Nickalls, R. W. & Mapleson, W. W. Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. *Br. J. Anaesth.* **91**, 170–174. https://doi.org/10.1093/bja/aeg132 (2003).

22. Kreuer, S. et al. Narcotrend or bispectral index monitoring during desflurane-remifentanil anesthesia: a comparison with a standard practice protocol. *Anesth. Analg.* **101**, 427–434. https://doi.org/10.1213/ane.0000157565.00359.e2 (2005).

**Author contributions**
Involvement in conception or design: Y.-Y.P., H.-C.C., M.-H.C., H.-F.L., J.-C.C., S.-C.W. Contributions to critical aspects of the research: Y.-Y.P., K.-C.H., H.-F.L., S.-C.W. Drafting the article: Y.-Y.P., M.-H.C. Revising the article: H.-C.C., S.-C.W. All authors reviewed the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to S.-C.W.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020